All News

cost.healthcare.jpg

Cost-Effectiveness of Biosimilars vs Leflunomide

d Jack Cush, MD

An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide.

Read Article
Stop,pills,water

ICYMI: Can Mycophenolate be Stopped in Stable SLE?

d Jack Cush, MD

In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.

Read Article
Dead Words Eulogy Cover Image

ICYMI: Dead Words Eulogy

d Jack Cush, MD

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

Read Article
FDG,PET,CT

ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?

d Jack Cush, MD

Imaging is often instrumental in diagnosing and staging patients diagnosed with giant cell arteritis. A new study compared the diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography and Magnetic Resonance Imaging in patients suspected of giant cell arteritis and found the CDUS had a numerically higher sensitivity (that was not statistically superior to other modalities).

Read Article
guidelines.recommendations.jpg

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

d Jack Cush, MD

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article
hidradenitis.jpg

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

d Jack Cush, MD

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.

Read Article
ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations https://t.co/abcs8RwJ5J https://t.co/wLOq4bK7qQ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI? https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes https://t.co/46g8ek286u https://t.co/FEFq4vkiPk

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 9 Facts about Leflunomide Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. https://t.co/WseVa589Fg. https://t.co/K4u00MbwEb

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA: SLE Review https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: BSR Guideline on Management of Sjogren’s Syndrome https://t.co/MMG3NmCeDl https://t.co/zKlR8jOkLD

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127, "PREDICTING PERSISTENT INFLAMMATORY ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM: DEVELOPMENT OF SCORES FOR RISK STRATIFICATION", at Eular 2024 in Vienna, Austria. https://t.co/Yzr9feNjjF https://t.co/BKVbDv3e4E

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA) https://t.co/JjhkQM672t. https://t.co/dM25kIcC26

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

RT @yuz6yusof #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare

Dr. John Cush RheumNow ( View Tweet)

10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab. #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr

Links:

Dr. John Cush RheumNow ( View Tweet)
×